⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20827026 | 1.00 | — | — | |
| SCHEMBL25682376 | 1.00 | — | — | |
| SCHEMBL4792671 | 0.91 | PDK1 (0.36) | — | |
| SCHEMBL11895879 | 0.85 | — | — | |
| SCHEMBL12477 | 0.85 | — | — | |
| SCHEMBL2302961 | 0.85 | — | — | |
| SCHEMBL7920447 | 0.85 | — | — | |
| Iodide SCHEMBL17907281 | 0.83 | — | — | |
| SCHEMBL23636603 | 0.79 | — | — | |
| SCHEMBL22490986 | 0.77 | PDK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023172940-A1 | METHODS FOR TREATING IMMUNE REFRACTORY LUNG CANCER | Revolution Medicines, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| WO-2021115413-A1 | NEUROMUSCULAR-BLOCKING DRUG AND PREPARATION METHOD THEREFOR | 江苏恒瑞医药股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
| US-8455471-B2 | Compositions of CHK1 inhibitors and cyclodextrin | ICOS CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | WISDOM WENDY A | 2010-01-28 | — | — | US | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008067027-A2 | COMPOSITIONS OF CHKL INHIBITORS AND CYCLODEXTRIN | ICOS CORPORATION (US) | 2008-06-05 | — | — | WO | disclosed |